Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts

Table 1 Clinicopathologic patient characteristics stratified by age for the Surveillance, Epidemiology, and End Results (SEER), Interdisciplinary Melanoma Cooperative Group (IMCG), and The Cancer Genome Atlas (TCGA) melanoma cohorts

Age groups	SEER (n = 304,476)							IMCG (n = 1241)							TCGA (n = 292)
	≤45		46–65		>65		p	≤45		46–65		>65		p	≤45		46–65		>65		p
	n	%	n	%	n	%		n	%	n	%	n	%		n	%	n	%	n	%
	72,976	24	117,158	38	114,342	38		308	25	439	35	494	40		71	24	128	44	93	32
Gender
Female	42,087	58	48,459	41	41,247	36	<0.001	172	56	186	42	197	40	<0.001	24	34	48	38	39	42	0.56
Male	30,889	42	68,699	59	73,095	64		136	44	253	58	297	60		47	66	80	62	54	58
Stage
I	22,625	83	46,599	79	42,064	71	<0.001	246	82	332	78	314	66	<0.001	22	40	25	24	12	14	<0.001
II	1860	7	5790	10	10,543	18		29	10	54	13	130	27		8	15	28	26	38	44
III	2123	8	4148	7	3695	6		24	8	38	9	35	7		20	36	48	45	33	38
IV	673	2	2357	4	2931	5		NA	NA	NA	NA	NA	NA		5	9	5	5	3	3
Thickness
<1.01	21,557	77	43,882	73	39,167	65	<0.001	210	68	265	60	239	48	<0.001	16	30	19	22	7	9	<0.001
1.01–2	3782	14	8612	14	9220	15		59	19	97	22	111	22		19	36	21	24	11	14
2.01–4	1633	6	4386	7	6747	11		23	7	48	11	86	17		7	13	16	18	25	32
>4	983	4	2915	5	5218	9		16	5	29	7	58	12		11	21	32	36	34	44
Ulceration
Absent	25,586	92	53,175	89	50,370	83	<0.001	272	88	374	85	374	76	<0.001	29	66	37	46	35	47	0.07
Present	2243	8	6388	11	10,213	17		36	12	65	15	119	24		15	34	44	54	39	53
Alive status
Alive	63,562	87	90,890	78	59,083	52	<0.001	295	96	394	90	388	79	<0.001	44	62	73	57	49	53	0.37
Died of melanoma	6387	9	12,625	11	15,285	13		13	4	30	7	48	10		26	37	50	39	37	40
Other	3027	4	13,643	12	39,974	35		0	0	15	3	58	12		1	1	5	4	7	8

ISSN: 1479-5876